The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.
 
Anne Patsouris
Travel, Accommodations, Expenses - Eisai; Novartis
 
Cecile Vicier
Travel, Accommodations, Expenses - Novartis; Pierre Fabre
 
Loic Campion
No Relationships to Disclose
 
Wilfried Gouraud
No Relationships to Disclose
 
Marta Jimenez
No Relationships to Disclose
 
Veronica Pezzella
No Relationships to Disclose
 
Andrea Loehr
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Mitch Raponi
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Ivan Bieche
No Relationships to Disclose
 
Celine Callens
No Relationships to Disclose
 
Fabrice Andre
Research Funding - AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Novartis; Roche